| Literature DB >> 33313428 |
Kiyoshi Egawa1, Shinji Saitoh2, Naoko Asahina1, Hideaki Shiraishi1.
Abstract
BACKGROUND: Angelman syndrome (AS) is neurodevelopmental disorder, causal gene of which is maternally expressed UBE3A. A majority of patients results from the large deletion of relevant chromosome which includes GABAA receptor subunit genes (GABARs) as well as UBE3A (AS Del). We previously reported aberrantly desynchronized primary somatosensory response in AS Del by using magnetoencephalography. The purpose of this study is to estimate cortical and subcortical involvement in the deficit of primary somatosensory processing in AS.Entities:
Keywords: AS Del, AS patients with a deletion in 15q11-q13; AS, Angelman syndrome; Angelman syndrome; CCT, Central conduction time; CZP, Clonazepam; GABARs, GABAA receptor subunit genes; GABAergic systems; Neurodevelopmental disorders; SEFs, Somatosensory-evoked fields; SSEPs, Short-latency somatosensory-evoked potentials; Somatosensory-evoked potentials; VPA, Valproic acid
Year: 2020 PMID: 33313428 PMCID: PMC7721653 DOI: 10.1016/j.ensci.2020.100298
Source DB: PubMed Journal: eNeurologicalSci ISSN: 2405-6502
Clinical profiles of the AS Del patients.
| Patient No. | Age/ sex | Anticonvulsant | Walking impairment | Language ability |
|---|---|---|---|---|
| 1 | 5/M | VPA | mild | simple words |
| 2 | 6/M | VPA, CZP | severe | no words |
| 3 | 8/F | VPA | severe | no words |
| 4 | 10/F | VPA | severe | no words |
| 5 | 10/M | VPA, CZP | moderate | simple words |
| 6 | 12/F | VPA, CZP | severe | simple words |
| 7 | 14/F | VPA, CZP | severe | no words |
| 8 | 28/M | VPA, CZP | severe | no words |
VPA: valproic acid, CZP: clonazepam, Classification of walking impairment: severe = impossible to walk without help, moderate = possible to walk without help, but is using a wheelchair, mild = possible to walk without help, and is not using a wheelchair.
Fig. 1SSEPs waveforms in control subjects (A) and AS Del patients (B). A and B show representative SSEPs of an 8-year-old control and an AS Del patient, respectively. Two trials are superimposed with black and gray traces in each recording. Traces from the electrode on the frontal and centroparietal area were superimposed with those from the subcortical components. The N20, P20 component was aberrantly prolonged in the AS Del patient, while there was no difference in subcortical components.
Mean latency and interval times for each component.
| AS Del | Controls | ||
|---|---|---|---|
| Latencies | |||
| N9o | 6.5 ± 0.4 | 6.5 ± 0.3 | N·S. |
| N9p | 7.9 ± 0.5 | 7.8 ± 0.4 | N.S. |
| N11o | 7.9 ± 0.4 | 7.7 ± 0.4 | N.S. |
| N11p | 8.7 ± 0.5 | 8.6 ± 0.5 | N.S. |
| N13p | 10.4 ± 0.6 | 10.6 ± 0.4 | N.S. |
| P13/14o | 9.8 ± 0.5 | 9.5 ± 0.3 | N.S. |
| P13/14p | 10.9 ± 0.5 | 11.4 ± 0.4 | N.S. |
| N20o | 14.0 ± 0.4 | 13.9 ± 0.4 | N.S. |
| N20p | 23.7 ± 1.7 | 16.5 ± 0.4 | <0.0001 |
| P20p | 27.6 ± 1.0 | 16.6 ± 0.4 | <0.0001 |
| Interval times | |||
| N11o - N20o | 1.4 ± 0.4 | 1.4 ± 0.5 | N.S. |
| P13/14o - N20o | 4.2 ± 0.3 | 4.0 ± 0.5 | N.S. |
| N11o - N20o | 6.1 ± 0.5 | 6.1 ± 0.4 | N.S. |
| N13p - N20p | 13.3 ± 5.6 | 5.9 ± 0.4 | <0.0001 |
| N20 duration | 23.0 ± 7.0 | 4.2 ± 0.7 | <0.0001 |
Values are mean ± SD (msec). N.S: not significant.